Stocks Health care MREO
NASDAQ · Health careMereo BioPharma Group plc (MREO)
It posted a net loss of $28.1M. In fiscal 2025 capital spending exceeded operating cash flow by $31M. At June 30, 2026 it held $30.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What Mereo BioPharma Group plc does
Mereo BioPharma Group plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MREO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $500K | -$41.9M | -$0.05 | -$31M |
| 2024 | $0 | -$43.3M | -$0.06 | -$32.8M |
| 2023 | $10M | -$29.5M | -$0.04 | -$21.1M |
| 2023 | $0 | -$42.2M | -$0.07 | -$48.8M |
Latest SEC filings
What Mereo BioPharma Group plc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 19, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026
- August 11, 2026
- August 11, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026Passive stake (5% or more) SCHEDULE 13G
- May 14, 2026
- May 12, 2026Quarterly results 8-K/A
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026
Questions about MREO
What does Mereo BioPharma Group plc do?
Mereo BioPharma Group plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MREO.
Is Mereo BioPharma Group plc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $28.1M.
When did Mereo BioPharma Group plc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the stock exchange listing notice from August 19, 2026.
Similar companies
Follow MREO
Get an email when Mereo BioPharma Group plc files with the SEC: results, executive changes, material agreements and annual reports.
Follow MREO: get an email when it filesWhere the numbers come from
Financial figures are the values Mereo BioPharma Group plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.